Content about Diabetes

DEERFIELD, Ill. — Drug maker Takeda Pharmaceutical has resubmitted regulatory approval applications for two drugs designed to treat diabetes, the company said.

Takeda announced the resubmission to the Food and Drug Administration of applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in the Takeda drug Actos.

BENTONVILLE, Ark. — Walmart has launched an effort to help diabetes patients save on their disease management products.

NEW YORK — Extended use of the oral DPP-4 inhibitor linagliptin to lower blood-glucose levels by Type 2 diabetes patients is effective, according to a new study.

A team of eight researchers — four of which work for drug maker Boehringer Ingelheim — examined 2,121 Type 2 diabetes patients that had taken part in four previous 24-week randomized, double-blind, placebo-controlled trials in order to monitor them for a further 78 weeks. The participants who took part in the extended trial came from 231 sites in 32 countries.

PHILADELPHIA — Jacques Duplessis on Monday pleaded guilty to engaging in a scheme to sell approximately 6,000 boxes of counterfeit LifeScan One Touch diabetic test strips that he purchased from suppliers in China and England, announced U.S. attorney Zane David Memeger.

LONDON — British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.

The deal, worth $14.25 per share, would give GSK full ownership of the lupus drug Benlysta (belimumab), as well as albiglutide, an experimental drug for diabetes, and darapladib, an experimental heart disease drug.

NEW YORK — Bristol-Myers Squibb is acquiring Amylin Pharmaceuticals, the drug maker said Friday.

Bristol announced that it would acquire Amylin for $5.3 billion, or $31 per share. The total value of the acquisition is about $7 billion, including $1.7 billion in Amylin's contractual payment and debt obligations.

An integrated wellness team approach to diabetes care can help patients not only improve their condition, but also lower their prescription costs, according to new research presented at the American Association of Clinical Endocrinologists’ 21st annual Scientific and Clinical Congress in Philadelphia.


WAUKESHA, Wis. — Hamacher Resource Group on Tuesday announced it will present “Marketing Diabetes in the Retail Setting” June 21 at the Marketing Diabetes Prevention and Awareness Conference in Atlanta.

Dave Wendland, VP and part of the owners group at HRG, will share ideas about how retail pharmacies can collaborate with suppliers to bring innovation to the diabetes care category to better serve patients, capture incremental sales and significantly grow the category’s reach.

CHICAGO — Diabetes and poor glucose control may be associated with greater cognitive decline in older adults, according to a new report from Archives of Neurology, a JAMA Network publication.

NEW YORK — Novo Nordisk and the Juvenile Diabetes Research Foundation on Wednesday announced the creation of a joint research and development team to discover and develop novel immunotherapies to prevent, treat and help cure Type 1 diabetes.

PHILADELPHIA — One-quarter of Type 2 diabetes patients do not take basal insulin as prescribed, while more than one-third suffer from hypoglycemia, according to a global survey funded by Novo Nordisk.

PHILADELPHIA — An investigational insulin being developed by Novo Nordisk significantly reduced the rate of hypoglycemia at night in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented at the 72nd Scientific Sessions of the American Diabetes Association.